The AVEN Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered for disruption of the AVEN gene in the human Jurkat T lymphocyte line. This heterogeneous pool of cells carries diverse loss-of-function mutations at the AVEN locus, enabling the study of AVEN-dependent phenotypes without the need for clonal isolation. The polyclonal format provides a cost-effective and efficient platform for initial target validation and functional genomic screening, preserving the genetic diversity of the parental population.
Jurkat cells are an immortalized T lymphocyte line derived from a patient with acute T cell leukemia. Widely employed in signal transduction research, they serve as a standard model for examining T cell receptor signaling cascades and the regulation of programmed cell death. Their leukemic origin confers high proliferative capacity and sensitivity to DNA-damaging chemotherapeutics such as etoposide and doxorubicin, making them an ideal host for studying chemoresistance and apoptotic pathways.
AVEN functions as an apoptosis regulator by directly binding the anti-apoptotic proteins BCL2 and BCL-XL (BCL2L1). This interaction prevents BCL2/BCL-XL from inhibiting pro-apoptotic effector BAX, thereby suppressing activation of initiator caspase-9 (CASP9) and executioner caspase-3 (CASP3). AVEN is transcriptionally upregulated by p53/TP53 in response to genotoxic stress, linking DNA damage signaling to cell fate decisions. Additionally, AVEN has been implicated in DNA double-strand break repair, potentially through interactions with repair complexes. The AVEN-centered network integrates BCL2, BCL2L1, BAX, CASP9, CASP3, and the apoptosome component cytochrome c (CYCS), coordinating survival and death signals.
In the Jurkat background, AVEN disruption is expected to lower the threshold for intrinsic apoptosis, especially upon genotoxic challenge. This knockout model is particularly relevant for dissecting drug resistance mechanisms in T-cell acute lymphoblastic leukemia (T-ALL), where AVEN overexpression is commonly observed. By ablating AVEN, researchers can probe the BCL2/BCL-XL?CAVEN regulatory axis and evaluate whether loss of AVEN sensitizes leukemic T cells to conventional chemotherapies. The model also permits investigation of potential crosstalk between apoptosis and T-cell receptor-mediated survival pathways.
Key applications include apoptosis assays using annexin V/7-AAD flow cytometry and caspase activity measurements, leukemia drug sensitivity profiling with etoposide or doxorubicin, DNA damage response analysis via ??-H2AX immunofluorescence, and functional genomics screens. The polyclonal population is compatible with western blotting for AVEN, BCL2, BCL-XL, and cleaved caspases to verify pathway modulation. This streamlined model accelerates hit discovery and mechanistic studies without the time and expense of clonal expansion. For additional product information or to place an order, contact Ascent Research.
